Discovering potential therapies for neurological disorders is a complex and difficult task. AmplifyBio’s team of preclinical neuroscience CRO researchers share a common goal with their clients: finding a cure for the devastating diseases of the central nervous system. From basic research to regulatory approval, AmplifyBio provides current and groundbreaking testing methods, a comprehensive range of neurobehavioral services, and a collaborative approach supporting programs in discovering and developing novel therapies. At AmplifyBio, we can easily incorporate Functional Observational Battery (FOB) assessments into the design of preclinical safety pharmacology and general toxicity studies. Let us know how our neurosciences team can help you achieve your research goals.
AmplifyBio’s preclinical neuroscience studies involve high-throughput testing using GLP-compliant and validated equipment with highly trained staff to assess the function and health of the central nervous system. AmplifyBio leverages decades of expertise to provide a thorough understanding of the potential impact of therapeutic interventions on the central nervous system and to identify any potential safety concerns that may need to be addressed before moving to clinical trials. The neurobehavioral phenotyping platforms available include:
General Behavior & Fine Motor
Cognition (Learning and Memory)
AmplifyBio aims to tackle a broad range of neurological disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and other conditions affecting the nervous system.
AmplifyBio focuses on various areas within neuroscience, such as neurodegeneration, neuroinflammation, synaptic plasticity, neuroprotection, and neuroregeneration.
Tier I Testing (Functional Observational Battery [FOB] or Modi ied Irwin Test)
Tier I testing provides the initial investigation into potential neurotoxic effects. The FOB assessment utilizes a battery of home cage, handling, open field, reflexes, and physiological tests to screen for potential neurotoxicity.
Tier II Testing
Tier II testing aims to characterize the nature of neurotoxicity seen in Tier I tests by quantifying effects on motor function, sensorimotor function, and cognitive behavior using complex tasks. These include:
Tier III Testing
Tier III testing helps uncover the mechanisms underlying neurotoxic effects seen in Tier I and Tier II tests.
Yes, AmplifyBio actively collaborates with leading academic institutions, research organizations, and industry partners to foster innovation, share knowledge, and accelerate the development of transformative treatments.
Our team of scientists has a long history of thought leadership in neurology, both as AmplifyBio and under the brand Battelle, prior to our spinoff in 2021. We’ve curated a number of resources for preclinical neurology studies as a result of that work.
AmplifyBio couples dedicated testing and related CRO services with a skilled team and access to the latest resources. This combination produces groundbreaking research for specialty products and assessments that can be analyzed for implementation in products and processes. Talk with us about your individual requirements and work with our specialists to develop an effective solution.